{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:48:12Z","timestamp":1794937692796,"version":"4.9.1"},"reference-count":21,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,13]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Rogocekib (development name CTX-712) is a first-in-class, orally available, highly potent, and selective small-molecule inhibitor of CDC2-like kinase, a key regulator of the RNA splicing process. Preclinical studies demonstrated antiproliferative activity on various in vitro and in vivo models of hematologic malignancies. Based on these findings, a phase 1 study of rogocekib was conducted to evaluate the safety and preliminary efficacy in patients with relapsed or refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS). Using a 3+3 design informed by previous solid tumor safety data, patients received 70 mg or 105 mg twice a week in capsule form. One dose-limiting toxicity of grade 4 pneumonia was observed in the 105 mg twice a week cohort. Among 12 patients with AML, complete remission (CR) was observed in 3 patients (25.0%), and CR with incomplete hematologic recovery was observed in 1 patient (8.3%). In patients with MDS (n = 2), CR was observed in 1 patient (50.0%). Pharmacokinetics analyses showed higher mean maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from time 0 to 24 hours post dose (AUC0-24) of rogocekib at 105 mg compared with 70 mg. Pharmacodynamics analysis showed that the relative magnitude of exon skipping in peripheral blood cells increased with exposure to rogocekib. Rogocekib demonstrated a manageable and tolerable safety profile in patients with hematologic malignancies. Currently, a phase 1\/2 study of rogocekib in relapsed\/refractory AML and higher risk MDS is ongoing in the United States (ClinicalTrials.gov identifier: NCT05732103). This trial was registered at the Japan Registry of Clinical Trials as jRCT2080224127.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017601","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T19:58:44Z","timestamp":1759867124000},"page":"262-272","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies"],"prefix":"10.1182","volume":"10","author":[{"given":"Hisayuki","family":"Yokoyama","sequence":"first","affiliation":[{"name":"1Department of Hematology and Cell Therapy, Yamagata University Hospital, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Tohoku University Hospital, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ando","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroatsu","family":"Iida","sequence":"additional","affiliation":[{"name":"4Department of Hematology, NHO Nagoya Medical Center, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Oncology, University of Fukui Hospital, Fukui, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"6Department of Hematology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"6Department of Hematology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Tanoue","sequence":"additional","affiliation":[{"name":"7Chordia Therapeutics Inc, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"7Chordia Therapeutics Inc, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Tozaki","sequence":"additional","affiliation":[{"name":"7Chordia Therapeutics Inc, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Takahara","sequence":"additional","affiliation":[{"name":"7Chordia Therapeutics Inc, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Shoji","sequence":"additional","affiliation":[{"name":"7Chordia Therapeutics Inc, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Mizutani","sequence":"additional","affiliation":[{"name":"7Chordia Therapeutics Inc, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Morishita","sequence":"additional","affiliation":[{"name":"7Chordia Therapeutics Inc, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5618-1985","authenticated-orcid":false,"given":"Robert","family":"Oda","sequence":"additional","affiliation":[{"name":"7Chordia Therapeutics Inc, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Miyake","sequence":"additional","affiliation":[{"name":"7Chordia Therapeutics Inc, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"8Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"7367","key":"2026011311213871600_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"8","key":"2026011311213871600_bib2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/blood.2019004260","article-title":"Splicing factor mutations in hematologic malignancies","volume":"138","author":"Chen","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2026011311213871600_bib3","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1182\/blood-2016-10-692400","article-title":"Splicing factor gene mutations in hematologic malignancies","volume":"129","author":"Saez","year":"2017","journal-title":"Blood"},{"issue":"17","key":"2026011311213871600_bib4","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1182\/bloodadvances.2021004556","article-title":"Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification","volume":"5","author":"van der Werf","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2026011311213871600_bib5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2026011311213871600_bib6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2022-159338","article-title":"CTX-712, a novel splicing modulator targeting myeloid neoplasms","volume":"140","author":"Yoda","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026011311213871600_bib7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2026011311213871600_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2026011311213871600_bib9","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"7 suppl","key":"2026011311213871600_bib10","article-title":"A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): efficacy and safety in solid tumor cohorts [abstract]","volume":"84","author":"Yamamoto","year":"2024","journal-title":"Cancer Res"},{"issue":"12","key":"2026011311213871600_bib11","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","article-title":"Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms","volume":"35","author":"Steensma","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"2026011311213871600_bib12","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10637-013-0046-5","article-title":"A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors","volume":"32","author":"Hong","year":"2014","journal-title":"Invest New Drugs"},{"issue":"15 suppl","key":"2026011311213871600_bib13","doi-asserted-by":"crossref","first-page":"e19507","DOI":"10.1200\/JCO.2020.38.15_suppl.e19507","article-title":"Tumor lysis syndrome (TLS) in acute myeloid leukemia (AML) patients treated with azacitidine (AZA) and venetoclax (VEN)","volume":"38","author":"Huang","year":"2020","journal-title":"JCO"},{"key":"2026011311213871600_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40364-019-0170-2","article-title":"Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia","volume":"7","author":"Zhao","year":"2019","journal-title":"Biomark Res"},{"issue":"suppl 1","key":"2026011311213871600_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2024-200393","article-title":"A phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated hematologic malignancies: a 2024 update","volume":"144","author":"Marvin-Peek","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2026011311213871600_bib16","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/s41375-019-0472-2","article-title":"Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia","volume":"33","author":"Pollyea","year":"2019","journal-title":"Leukemia"},{"issue":"22","key":"2026011311213871600_bib17","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-13-0485","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors","volume":"19","author":"Eskens","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2026011311213871600_bib18","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1182\/blood-2023-173496","article-title":"Phase 1\/2 multicenter, open-label study of CTX-712 in patients with relapsed\/refractory acute myeloid leukemia and higher risk myelodysplastic syndromes","volume":"142","author":"Al-Kali","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2026011311213871600_bib19","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood-2018-04-843771","article-title":"Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations","volume":"132","author":"Pellagatti","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2026011311213871600_bib20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2019-131559","article-title":"CTX-712, a novel Clk inhibitor targeting myeloid neoplasms with SRSF2 mutation","volume":"134","author":"Yoda","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2026011311213871600_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2022.12.002","article-title":"Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/262\/2497507\/blooda_adv-2025-017601-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/262\/2497507\/blooda_adv-2025-017601-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:21:44Z","timestamp":1768321304000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/1\/262\/547633\/Phase-1-study-of-rogocekib-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017601","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,13]]},"published":{"date-parts":[[2026,1,13]]}}}